MRTX - ミラティ・セラピュ―ティックス （Mirati Therapeutics Inc.） ミラティ・セラピュ―ティックスMRTXのチャート
MRTXの企業情報
| symbol | MRTx |
|---|---|
| 会社名 | Mirati Therapeutics Inc （ミラティ・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Mirati Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265 MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC) and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable spectrum-selective histone deacetylase (HDAC) inhibitor which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL) specifically focusing on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). ミラティ・セラピュ―ティックスは、臨床期の米国バイオ医薬品企業。一部の癌患者の治療のため医薬品開発に焦点を当てる。主な製品は、｢MGCD265｣、｢MGCD516｣と｢mocetinostat｣。非小細胞肺癌、頭頸部の扁平上皮癌、および他の固形腫瘍、骨髄異形成症候群を有する患者を治療するために製品を開発する。 Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. |
| 本社所在地 | 9393 Towne Centre Drive Suite 200 San Diego CA 92121 USA |
| 代表者氏名 | Rodney W. Lappe ロドニー・W・ラッペ |
| 代表者役職名 | Executive Independent Chairman of the Board |
| 電話番号 | +1 858-332-3410 |
| 設立年月日 | 41365 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 51人 |
| url | www.mirati.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mrtx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -78.67100 |
| 終値（lastsale） | 44.38 |
| 時価総額（marketcap） | 1436071738.92 |
| 時価総額 | 時価総額（百万ドル） 1294.665 |
| 売上高 | 売上高（百万ドル） 9.46700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 134.481 |
| 当期純利益 | 当期純利益（百万ドル） -76.82300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Mirati Therapeutics Inc revenues increased from $0K to $9.5M. Net loss increased 18% to $42.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and develpment balancng value increase of 55% to $34.9M (expense) Stock-based Compensation in SGA increase from $2.1M to $4.3M (expense). |
MRTXのテクニカル分析
MRTXのニュース
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update 2023/03/28 12:00:00 Benzinga
Total revenue on FYARRO® sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected in the second quarter of 2023 Conference call to be held today at 8:30 am EDT LOS ANGELES , March 28, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI ), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the fourth quarter and full-year 2022. "2022 was a year marked by successive milestones with the launch of FYARRO, the start of the PRECISION 1 trial, strengthening our balance sheet with a $72.5 million financing, taking our cash runway into 2025, and collaborating on a new combination of nab -sirolimus with Mirati''s adagrasib," said Scott Giacobello , CFO and interim President and CEO of Aadi Bioscience. "We look forward to another year of advancements as we enter 2023 including the progression in our first collaboration, which is expected to initiate in the second quarter.
Mirati Therapeutics (MRTX) Investor Presentation - Slideshow (NASDAQ:MRTX) 2023/03/24 13:30:53 Seeking Alpha
The following slide deck was published by Mirati Therapeutics, Inc.
Mirati''s Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market (NASDAQ:MRTX) 2023/03/20 07:43:10 Seeking Alpha
Mirati Therapeutics''s Krazati could capture a significant share of the 2L KRAS G12C-mutated NSCLC market. Click here to read why MRTX stock is a Buy.
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference 2023/03/06 21:30:00 PR Newswire
SAN DIEGO, March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. / 9:00 a.m. E.T. Ben Hickey, chief commercial officer, and Alan Sandler,…
Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M 2023/02/28 21:41:06 Seeking Alpha
Mirati Therapeutics press release (MRTX): Q4 GAAP EPS of -$3.51 beats by $0.16.Revenue of $0.93M (+210.0% Y/Y) misses by $1.72M.
Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M 2023/02/28 21:41:06 Seeking Alpha
Mirati Therapeutics press release (MRTX): Q4 GAAP EPS of -$3.51 beats by $0.16.Revenue of $0.93M (+210.0% Y/Y) misses by $1.72M.
Mirati: Q4 Earnings Snapshot 2023/02/28 21:36:33 WTOP
SAN DIEGO (AP) — SAN DIEGO (AP) — Mirati Therapeutics Inc. (MRTX) on Tuesday reported a loss of $202.5 million…
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates 2023/02/28 21:01:00 PR Newswire
SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates. "2022 was a momentous year for Mirati,…
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm 2023/02/27 15:00:00 GlobeNewswire
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company’s long-term investors.
Can you now get a good deal on Mirati Therapeutics Inc.’s shares? 2023/02/23 12:54:00 US Post News
Mirati Therapeutics Inc. (NASDAQ:MRTX) marked $46.03 per share on Wednesday, up from a previous closing price of $45.35. While Mirati Therapeutics Inc. has overperformed by 1.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRTX fell by -49.59%, with highs and lows ranging from $101.30 to […]
MRTX stock jumps as Amgen meets key goal for rival cancer drug (NASDAQ:MRTX) 2022/08/31 10:49:01 Seeking Alpha
The shares of clinical-stage biotech Mirati Therapeutics (MRTX) added ~11% in the pre-market trading Wednesday after Amgen (AMGN) announced a lung cancer medication that rivals…
Mirati Therapeutics Inc. (MRTX)’s Stock Price Falls Due To Weak Fundamental Momentum 2022/08/08 19:00:00 Marketing Sentinel
Mirati Therapeutics Inc. (NASDAQ:MRTX) has a beta value of 0.99 and has seen 1.0 million shares traded in the recent trading session. The company, currently valued at $4.33B, closed the recent trade at $91.51 per share which meant it gained $4.95 on the day or 5.72% during that session. The MRTX stock price is -114.17% … Mirati Therapeutics Inc. (MRTX)’s Stock Price Falls Due To Weak Fundamental Momentum Read More »
MRTX stock gains as Amgen posts new combination data for rival cancer drug (NASDAQ:MRTX) 2022/08/08 13:21:44 Seeking Alpha
Mirati Therapeutics (MRTX) added ~10% in the pre-market Monday after Amgen (AMGN) posted Phase 1 data for the rival KRAS inhibitor Lumakras, highlighting liver side effects of the…
Mirati Therapeutics PT Raised to $88 at BofA Securities 2022/08/08 09:54:17 Investing.com
https://www.investing.com/news/pro/mirati-therapeutics-pt-raised-to-88-at-bofa-securities-432SI-2866362
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2022/08/04 20:30:00 PR Newswire
SAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 56 new employees with a grant date of August 1, 2022, as equity inducement awards outside of the…